Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL

Kerry Rogers, MD
Published: Friday, Dec 22, 2017



Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

This study investigates a chemotherapy-free combination, explains Rogers. Traditionally, there has been success with chemotherapy combination treatments. However, side effects of chemotherapy are difficult for many patients.

According to Rogers, these 3 agents have different mechanisms of action and non-overlapping toxicity profiles, making them an interesting combination to study.
 


Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

This study investigates a chemotherapy-free combination, explains Rogers. Traditionally, there has been success with chemotherapy combination treatments. However, side effects of chemotherapy are difficult for many patients.

According to Rogers, these 3 agents have different mechanisms of action and non-overlapping toxicity profiles, making them an interesting combination to study.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x